ARTICLE | Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

March 10, 2018 2:36 PM UTC

Armed with cardiovascular outcomes data for Praluent alirocumab and a fresh cost-effectiveness analysis from the Institute for Clinical and Economic Review (ICER), Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have a proposition for payers: reduce barriers to access in high-risk patients and the partners will offer up to a 69% discount to the PCSK9 inhibitor’s list price.

“We commit to working with all health plans that agree to remove access barriers for high-risk patients to offer a more cost-effective net price for Praluent,” said Regeneron President and CEO Leonard Schleifer in a statement issued March 10 following the results of ODYSSEY OUTCOMES study...